Canbas listed its stocks on the Mothers Index of the Tokyo Stock Exchange on September 17th, 2009.

Canbas is a venture company started by members who share the same feeling: "We want to heal cancer."
Focusing on the cell cycle, we are undertaking the challenge of developing anticancer drugs that are kind to the body. CBP501, the first compound to come out of the R&D pipeline, is currently undergoing Phase 2 clinical trials in the US.

However, the development of medicines has inherent risk, because it takes a long time and a lot of money to do so.

The candidate compounds that Canbas is working on are currently still in development, and at the current time, the company has no revenue from product sales. Also, it is expected to take time and money before the product is put on the market, and there is no real guarantee that the product will ever make the market.
For Canbas, listing the company's stocks is an opportunity to finance sustainable development into the future, but at the same time it is also moving the risk burden from venture capitalists to the everyday investor like you.

This heavy responsibility is deeply recognized by the employees of this company, and our corporate philosophies of "Be Fair" and "Continue down the correct path in the shortest distance and time in a scientific, logical, and economical manner" are always in our minds as we put forth full effort in reaching our business objectives.

We hope to have your guidance and encouragement going forward.